January 3rd, 2012
Bariatric Surgery Cuts Cardiovascular Deaths and Events
Larry Husten, PHD
Bariatric surgery results in significant reductions in cardiovascular deaths and events, according to a new study from Sweden published in JAMA. But one expert cautions that the results do not mean that obese patients without other weight-related complications should undergo surgery.
Analyzing data from more than 4000 obese patients enrolled in the ongoing Swedish Obese Subjects (SOS) study, Lars Sjöström and colleagues found that bariatric surgery was associated with a reduction in cardiovascular events and deaths after a median follow-up of 14.7 years. (The investigators had previously reported a reduction in total mortality in the surgery group.)
- CV deaths: 28 in the surgery group versus 49 in the control group (HR 0.47, CI 0.29- 0.76, p=0.002)
- MI or stroke: 199 versus 234, (HR 0.67, CI 0.54-0.83, p<0.001)
In a surprising finding, the investigators found no significant association between either weight at baseline or weight loss after surgery and cardiovascular events. The authors speculate this may have been due to the low statistical power of the study to detect an association or, alternatively, that the greatest benefit was derived from the initial modest weight loss caused by the surgery.
Taken with previous reports, the results, write the authors, “demonstrate that there are many benefits to bariatric surgery and that some of these benefits are independent of the degree of the surgically induced weight loss.”
In an accompanying editorial, Edward Livingston writes that “because the expected health benefits do not necessarily exceed the risks of weight loss operations, obese patients without other weight-related complications generally should not undergo bariatric surgery.” He suggests that the NIH convene a new expert panel “to rigorously assess the available evidence and provide updated recommendations for bariatric procedures for the treatment of obesity.”
Categories: Cardiac Surgery, General, Prevention
Tags: bariatric surgery, weight loss
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Glucocorticoids in Kawasaki Disease — Refining Indications and the Science April 16, 2026Kawasaki disease is the most common cause of acquired heart disease in children in the developed world.1 Although Kawasaki disease manifests with acute, transient systemic signs, its long-term morbidity derives from necrotizing vasculitis that predominantly affects the coronary arteries.2,3 The primary goal of therapy during the...
- Asundexian for Secondary Stroke Prevention April 16, 2026In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding.
- Asundexian for Noncardioembolic Ischemic Stroke April 16, 2026Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to...
- Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk April 16, 2026Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk.
- Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease April 16, 2026In a randomized trial involving 3208 children with Kawasaki disease, adding prednisolone to standard primary therapy did not reduce the incidence of coronary-artery lesions at 1 month.
- Glucocorticoids in Kawasaki Disease — Refining Indications and the Science April 16, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
